Type Public Area served Worldwide Revenue 4.1 billion USD | Founded 1988 CEO Leonard Schleifer | |
 | ||
Traded as NASDAQ: REGN
NASDAQ-100 Component
S&P 500 Component Industry Pharmaceuticals; Biotech Key people Leonard Schleifer (CEO)
George Yancopoulos, CSO Stock price REGN (NASDAQ) US$ 373.00 +7.98 (+2.19%)24 Mar, 4:00 PM GMT-4 - Disclaimer Headquarters Tarrytown, New York, United States SVPs Thomas Daly (Strategy, Investor Relations, Preclinical Development, Protein Chemistry) Profiles | ||
The next big thing in biotech regeneron pharmaceuticals
Regeneron Pharmaceuticals, Inc. is a biotechnology company headquartered in Eastview, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities (thus the name), it branched out into the study of both cytokine and tyrosine kinase receptors.
Contents
- The next big thing in biotech regeneron pharmaceuticals
- Company history
- Marketed products
- Technology platforms
- References
Company history
Regeneron has two products in development based on aflibercept, a VEGF inhibitor, and rilonacept, an interleukin-1 blocker. VEGF is a protein that normally stimulates the growth of blood vessels, and interleukin-1 is a protein that is normally involved in inflammation. On March 26, 2012 Bloomberg announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72% more than the leading brands. It is believed this new drug will greatly reduce heart disease in patients around the world. The medicine, one in a class of drugs targeting the PCSK9 gene, reduced patients’ average LDL cholesterol levels to as little as 34 milligrams per deciliter after 12 weeks in the mid- stage study, presented on March, 2012 at the American College of Cardiology meeting in Chicago.
In July 2015, the company announced a new global collaboration with Sanofi to discover, develop, and commercialise new immuno-oncology drugs, which could generate more than $2 billion for Regeneron, with $640 million upfront, $750 million for proof of concept data and $650 million from the development of REGN2810.
Marketed products
EYLEA (aflibercept injection): Approved by the U.S. Food and Drug Administration (FDA) in November 2011. EYLEA developed to treat a common cause of blindness in the elderly.
ARCALYST (rilonacept) for specific, rare autoinflammatory conditions. Approved by the FDA in February 2008.
ZALTRAP (aflibercept injection) for metastatic colorectal cancer: Approved by the FDA in August 2012.
PRALUENT (Alirocumab) indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein (LDL) cholesterol. Approved by FDA on 24 July 2015
Technology platforms
Trap Fusion Proteins: Regeneron’s novel and patented Trap technology creates high-affinity product candidates for many types of signaling molecules, including growth factors and cytokines. The Trap technology involves fusing two distinct fully human receptor components and a fully human immunoglobulin-G constant region.
Fully Human Monoclonal Antibodies: Regeneron has developed a suite (VelociSuite) of patented technologies, including VelocImmune and VelociMab, that allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high-quality, fully human antibodies drug candidates addressing these targets.